Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Capital Expenditures (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Capital Expenditures for 4 consecutive years, with $250000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 12600.0% to $250000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $738000.0 through Dec 2025, up 97.33% year-over-year, with the annual reading at $738000.0 for FY2025, 97.33% up from the prior year.
  • Capital Expenditures hit $250000.0 in Q4 2025 for Taysha Gene Therapies, up from $108000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $18.2 million in Q3 2022 to a low of -$3.4 million in Q3 2023.
  • Historically, Capital Expenditures has averaged $1.4 million across 4 years, with a median of $98000.0 in 2022.
  • Biggest YoY gain for Capital Expenditures was 18471.43% in 2023; the steepest drop was 154.55% in 2023.
  • Year by year, Capital Expenditures stood at $2.3 million in 2022, then tumbled by 117.54% to -$405000.0 in 2023, then soared by 99.51% to -$2000.0 in 2024, then soared by 12600.0% to $250000.0 in 2025.
  • Business Quant data shows Capital Expenditures for TSHA at $250000.0 in Q4 2025, $108000.0 in Q3 2025, and $357000.0 in Q2 2025.